Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer

scientific article published on 10 December 2013

Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3892/MCO.2013.223
P932PMC publication ID3917783
P698PubMed publication ID24649335

P50authorNobuo YaegashiQ59160672
Yoshihito YokoyamaQ87618863
Toru SugiyamaQ88144723
Yukihiro TeradaQ88518648
Masayuki FutagamiQ90431145
Keiya FujimoriQ92612600
Tadao TakanoQ114249699
Hideki MizunumaQ114250977
Toru TaseQ114560750
Hirohisa KurachiQ114560752
Takanobu KojimaharaQ114560780
P2093author name stringNaoki Sato
Hiroshi Nishiyama
Jun Watanabe
Fumiharu Miura
P2860cites workPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyQ33348987
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatinQ34604181
Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent diseaseQ34826559
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsQ36467605
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerQ36822179
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group studyQ44315213
Incorporation of bevacizumab in the primary treatment of ovarian cancerQ44579933
Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?Q44927653
[Second-line treatment using novel chemotherapeutic and biologic agents].Q46001580
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapseQ46082130
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.Q53227029
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.Q53263238
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.Q53300225
Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsQ68927282
Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiationQ83859008
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialQ84574337
P433issue2
P921main subjectovarian cancerQ172341
P304page(s)212-218
P577publication date2013-12-10
P1433published inMolecular and Clinical OncologyQ27725125
P1476titleRedistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer
P478volume2

Reverse relations

cites work (P2860)
Q47586504Biological functions and role of CCN1/Cyr61 in embryogenesis and tumorigenesis in the female reproductive system (Review).
Q40768444Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer
Q38818448Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models
Q34631089The level of RECQL1 expression is a prognostic factor for epithelial ovarian cancer

Search more.